Subcutaneous (SC) lecanemab is predicted to achieve comparable efficacy and improved safety compared to lecanemab IV in early Alzheimer’s disease (AD)

小瓶 最大值 药代动力学 医学 生物利用度 药效学 β淀粉样蛋白 药理学 化学 内科学 色谱法 阿尔茨海默病 疾病
作者
Brian A. Willis,Natasha Penner,Sumit Rawal,Jagadeesh Aluri,Larisa Reyderman
出处
期刊:Alzheimers & Dementia [Wiley]
卷期号:19 (S24) 被引量:3
标识
DOI:10.1002/alz.082852
摘要

Abstract Background Lecanemab is an anti‐amyloid antibody that has been approved by the United States FDA for treatment of early AD under the accelerated approval pathway. Lecanemab 10 mg/kg every 2 weeks (Q2W) intravenously (IV) was shown in the CLARITY‐AD trial to slow the progression of AD. Pharmacokinetic/pharmacodynamic (PK/PD) modeling demonstrated that lecanemab average steady‐state concentrations (Cav,ss) are associated with amyloid plaque lowering and efficacy, while maximum steady‐state concentrations (Cmax,ss) are correlated with the incidence of amyloid‐related imaging abnormalities‐edema (ARIA‐E). SC lecanemab is being developed to improve patient convenience and safety profile by lowering the rate of ARIA‐E. Method Two single‐dose studies (NCT05045716 and NCT05533801) were conducted in healthy subjects to establish absolute bioavailability of a drug‐in‐vial (SC vial) formulation and to compare PK of SC vial and autoinjector (AI). In the first study, subjects were administered 10 mg/kg IV Q2W or 700 mg SC vial once‐weekly (QW) lecanemab (n = 30/arm). In the second study, subjects were administered 720 mg SC vial or 720 mg AI lecanemab (n = 80/arm). Serum lecanemab concentrations were measured for 50 days, and noncompartmental PK parameters were calculated. Result The absolute bioavailability of SC vial was 49.7% (90%CI:43.5‐56.8). Cmax following SC vial was 22.8% of IV (59.8 vs 262 µg/mL). AI had 20% higher AUC than SC vial (20900 vs 17400 µg.h/mL). PK modeling demonstrated that Cav,ss following 720 mg QW, administered by SC vial or AI, is similar to 10 mg/kg IV lecanemab. Cmax,ss following SC vial or AI will be approximately half that of IV. Based on these results, exposure‐response models predict similar amyloid plaque lowering and efficacy for IV, SC vial and AI. ARIA‐E rates are expected to be reduced with SC formulations (APOE4 carriers, IV:14.0%, SC Vial:4.8%, AI:5.6%; APOE4 noncarriers, IV:5.4%, SC Vial:1.7%, AI:2.0%). Conclusion 720mg QW using SC vial or AI results in comparable Cav,ss to 10 mg/kg Q2W IV lecanemab and is expected to have similar amyloid plaque lowering and efficacy. SC lecanemab has the potential to substantially lower incidence of ARIA‐E compared to IV. Ongoing studies will confirm the safety and efficacy profiles of SC lecanemab.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
不吃香菜发布了新的文献求助10
刚刚
qianzhihe发布了新的文献求助10
刚刚
xlf完成签到,获得积分10
1秒前
Jasper的应助被小鱼采纳,获得10
1秒前
包亚鑫发布了新的文献求助10
2秒前
辛勤的鹰完成签到 ,获得积分10
3秒前
啵子发布了新的文献求助10
3秒前
wanci的应助被霁月采纳,获得10
3秒前
宋清华发布了新的文献求助10
4秒前
这篇论文就发个尊贵的顶就好完成签到 ,获得积分10
5秒前
5秒前
5秒前
dit完成签到,获得积分10
6秒前
6秒前
7秒前
凶狠的璎发布了新的文献求助20
7秒前
赵世坤完成签到,获得积分10
7秒前
科研通AI6.3的应助被BBB采纳,获得10
7秒前
不要酸橘子完成签到,获得积分10
8秒前
香蕉觅云的应助被Outlier采纳,获得30
9秒前
10秒前
小易不易完成签到 ,获得积分10
10秒前
怀素完成签到,获得积分10
10秒前
Poem完成签到 ,获得积分10
10秒前
10秒前
11秒前
Hello的应助被木炭采纳,获得10
11秒前
11秒前
顾村发布了新的文献求助10
12秒前
JamesPei的应助被锂离子采纳,获得10
12秒前
脑洞疼的应助被不吃香菜采纳,获得10
12秒前
小蘑菇的应助被牛得伐采纳,获得10
13秒前
乐观的白开水完成签到,获得积分10
14秒前
LENZ发布了新的文献求助50
15秒前
思源的应助被long采纳,获得10
15秒前
wg发布了新的文献求助10
15秒前
有医无药完成签到,获得积分10
15秒前
15秒前
16秒前
皮卡丘发布了新的文献求助10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188013
求助须知:如何正确求助?哪些是违规求助? 9575913
关于积分的说明 21844012
捐赠科研通 7785789
什么是DOI,文献DOI怎么找? 3435148
关于科研通互助平台的介绍 2559521
邀请新用户注册赠送积分活动 2482051